Arbutus Biopharma Corporation (ABUS) has a negative trailing P/E of -25.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 12.8 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -3.98%, forward earnings yield 7.82%.
Criteria proven by this page:
Overall SharesGrow Score: 55/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -0.3 | 0.00 | 0.64 | 86.65 | - |
| 2017 | -3.3 | 0.04 | 1.51 | 25.81 | - |
| 2018 | -3.7 | 0.11 | 1.06 | 35.90 | 4.76% |
| 2019 | -1.0 | -0.01 | 2.18 | 26.40 | - |
| 2020 | -4.2 | 0.06 | 2.64 | 38.94 | - |
| 2021 | -5.4 | 0.36 | 2.44 | 37.61 | 2.94% |
| 2022 | -5.1 | 0.14 | 2.57 | 9.01 | - |
| 2023 | -5.7 | 1.31 | 3.91 | 22.87 | - |
| 2024 | -8.7 | 0.64 | 6.23 | 98.35 | - |
| 2025 | -27.5 | 0.50 | 12.04 | 65.44 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-7.24 | $1.5M | $-384.1M | -25606.7% |
| 2017 | $-1.54 | $10.7M | $-84.4M | -788.8% |
| 2018 | $-1.03 | $5.9M | $-57.1M | -967.8% |
| 2019 | $-2.69 | $6.01M | $-153.72M | -2557.4% |
| 2020 | $-0.86 | $6.91M | $-65.21M | -943.2% |
| 2021 | $-0.73 | $10.99M | $-77.35M | -704% |
| 2022 | $-0.46 | $39.02M | $-69.46M | -178% |
| 2023 | $-0.44 | $18.14M | $-72.85M | -401.6% |
| 2024 | $-0.38 | $6.17M | $-69.92M | -1133% |
| 2025 | $-0.17 | $14.08M | $-33.5M | -237.9% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.16 | $-0.23 – $-0.09 | $1M | $653.42K – $1.35M | 1 |
| 2027 | $-0.05 | $-0.07 – $-0.03 | $8.83M | $8.83M – $8.83M | 1 |
| 2028 | $-0.14 | $-0.20 – $-0.08 | $55.95M | $36.56M – $75.34M | 1 |
| 2029 | $0.34 | $0.19 – $0.49 | $173.53M | $113.39M – $233.67M | 1 |
